Исследование частоты аллельных вариантов гена CYP2C9 в популяции г. Москвы у пациентов с АГ I-II степени, получающих фармакотерапию ирбесартаном
https://doi.org/10.37489/2588-0527-2022-2-28-29
Abstract
Цель. Оптимизация фармакотерапии блокаторами рецепторов ангиотензина II пациентов с АГ путём персонализации режима дозирования на основании генотипирования по полиморфным маркёрам CYP2C9.
About the Author
Е. РеброваRussian Federation
References
1. Franklin SS, Lopez VA, Wong ND, Mitchell GF, Larson MG, Vasan RS, Levy D. Single versus combined blood pressure components and risk for cardiovascular disease: the Framingham Heart Study. Circulation. 2009 Jan 20;119(2):243–250. DOI: 10.1161/CIRCULATIONAHA.108.797936.
2. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018 Oct;36(10):1953–2041. DOI: 10.1097/ HJH.0000000000001940.
3. Chazova IE, Zhernakova YuV on behalf of the experts. Clinical guidelines. Diagnosis and treatment of arterial hypertension. Systemic Hypertension. 2019;16(1):6–31. (In Russ). DOI: 10.26442/2075082X.2019.1.190179.
4. Rodgers JE, Patterson JH. Angiotensin II-receptor blockers: clinical relevance and therapeutic role. Am J Health Syst Pharm. 2001 Apr 15;58(8):671– 663. DOI: 10.1093/ajhp/58.8.671.
5. Sychev DA, Shprakh VV, Kitaeva EYu, Mirzaev KB. Polymorphism of CYP2C19 and ABCB1 genes asso cia ted with changes in the activity of clopidogrel in patients with ischemic stroke: clinial and ethnic aspects. Klinicheskaya farmakologiya I terapiya = Clin Pharmacol Ther. 2019;28(3):79–84. (In Russ). DOI: 10.32756/0869-5490-2019-3-79-84.
Review
For citations:
. Pharmacogenetics and Pharmacogenomics. 2022;(2):28-29. (In Russ.) https://doi.org/10.37489/2588-0527-2022-2-28-29